Loading...
•
Jun 30, 2020
Elanco Q2 2020 Earnings Report
Elanco's financial performance was significantly affected by actions to reduce channel inventory and by pandemic-related impacts.
Key Takeaways
Elanco Animal Health reported a decrease in total revenue by 25% to $586.3 million, primarily due to channel inventory reduction and the COVID-19 pandemic. The company reported a net loss of $53.2 million, or $0.13 per diluted share.
Completed channel inventory reduction in line with expectations.
Delivered 2% price growth across the portfolio.
Reaccelerated growth of innovation portfolio driven by increased market share for recent companion animal launches.
Effectively managed operating expenses and cash during this volatile time.
Forward Guidance
For the third quarter of 2020, legacy Elanco Total Revenue is expected to be between $660 and $710 million. Core Revenue, excluding Strategic Exits, is expected to be between $650 and $700 million, including our estimate of approximately $30 to $50 million in COVID-19 related headwinds.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...